A Phase I, Two Centre, Double-Blind, Randomized, Cross-Over Study to Evaluate AZD1386 in Single Doses of 30 mg and 95 mg Compared to Placebo in a Multimodal Experimental Pain Model on Esophageal Sensitivity and Development of Sensitization in Healthy Male Volunteers

Trial Profile

A Phase I, Two Centre, Double-Blind, Randomized, Cross-Over Study to Evaluate AZD1386 in Single Doses of 30 mg and 95 mg Compared to Placebo in a Multimodal Experimental Pain Model on Esophageal Sensitivity and Development of Sensitization in Healthy Male Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 10 May 2011

At a glance

  • Drugs AZD 1386 (Primary)
  • Indications Visceral pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 May 2011 Results presented at the Digestive Disease Week 2011.
    • 16 Mar 2011 Results published in the Alimentary Pharmacology and Therapeutics.
    • 02 Sep 2009 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top